TPO and autoimmune thrombocytopenic purpura: Although many drugs are available for refractory ITP, including TPO-RA and rituximab, as well as treatments including splenectomy, immunosuppressants, and novel therapies, individualized management is usually based on patient preference, side effects, previous treatment received, comorbidities, and cost associated with the treatment.